Aug 12, 2020
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020
Aug 12, 2020
New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients
Jun 22, 2020
Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029
Jun 17, 2020
The Leukemia & Lymphoma Society Today Announces a Collaboration with the National Cancer Institute and Children's Oncology Group on a Global Master Clinical Trial for Children with Acute Leukemia
Jun 15, 2020
Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML
Jun 13, 2020
EHA25Virtual: A Paradigm Shift for the Treatment of Newly Diagnosed Older Acute Myeloid Leukemia Patients
Jun 13, 2020
VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients
Jun 12, 2020
Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed Acute Myeloid Leukemia at Virtual EHA Annual Congress 2020
Jun 10, 2020
Ryvu Therapeutics Reports First Quarter 2020 Financial Results
Jun 04, 2020
Moleculin Announces Submission to Expand Clinical Sites in European AML Trial
May 19, 2020
Protocol First Announces Strategic Investment from The Leukemia & Lymphoma Society (LLS) to Advance Clinical Trial Execution
May 19, 2020
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States
May 14, 2020
Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings
May 14, 2020
Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Presentation at 25th EHA Congress
May 14, 2020
25th EHA Congress: Menarini Ricerche Discloses First Results From the Clinical Study on SEL24/MEN1703
Apr 29, 2020
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia
Apr 28, 2020
Cardioprotective Drug Prevents Severe Cardiac Events in Children Undergoing Chemotherapy for Acute Myeloid Leukemia
Apr 27, 2020
Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias
Mar 28, 2020
Ryvu Therapeutics Receives Orphan Drug Designation From FDA for SEL120 to Treat Acute Myeloid Leukemia
Mar 26, 2020
Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia